DaVita price target raised to $115 from $100 at Truist

Truist analyst David MacDonald raised the firm’s price target on DaVita to $115 from $100 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Healthcare Services. The firm remains bullish on the group’s long-term tailwinds, but utilization creates near-term uncertainty. The recent Medicare utilization comments have caused MCO skittishness, but Truist also “sees offsets” and believes that valuations in the sector remain “noticeably discounted”, the analyst tells investors in a research note. The firm is also encouraged by cost savings and efficiency initiatives in place at the company.